Agilent Technologies Reports 7% Revenue Growth to $1.798 Billion, Net Income Declines

Agilent Technologies, Inc. reported a net revenue of $1,798 million for the three months ended January 31, 2026, marking a 7% increase from $1,681 million in the same period last year. The growth was driven by contributions from all segments and geographic regions, with a favorable impact of 3 percentage points attributed to foreign currency movements. The Life Sciences and Diagnostics Markets segment saw a 5% increase in revenue, while the Agilent CrossLab segment experienced a 9% rise, and the Applied Markets segment grew by 7%. However, net income for the quarter decreased to $305 million from $318 million year-over-year, resulting in diluted earnings per share of $1.07 compared to $1.11 in the prior year.

The company's total costs and expenses rose to $1,445 million from $1,305 million, primarily due to increased selling, general, and administrative expenses, which surged by 16% to $476 million. Research and development expenses also increased by 4% to $117 million. The overall operating margin decreased to 19.7% from 22.4% in the previous year, reflecting the impact of higher tariffs, wage increases, and restructuring costs. Despite these challenges, Agilent's cash provided by operations was $268 million, down from $431 million in the same quarter last year, largely due to increased payments under variable and incentive pay programs.

In terms of strategic developments, Agilent continued its share repurchase program, retiring 1.050 million shares for $152 million during the quarter. The company also declared a quarterly dividend of $0.255 per share, totaling approximately $72 million, which is consistent with the previous year. Agilent's headcount increased to approximately 18,000, up from 17,900 a year earlier, indicating ongoing investment in human resources to support growth.

Looking ahead, Agilent remains optimistic about long-term growth opportunities across its key markets, despite the adverse impact of tariffs on costs. The company plans to implement mitigation strategies, including supply chain optimization and targeted pricing actions, to protect margins. Agilent's management is focused on enhancing customer experience and expanding its applications and solutions portfolio, particularly in the life sciences and diagnostics sectors, where demand for nucleic acid-based therapeutics is expected to rise.

Overall, while Agilent Technologies faced challenges in profitability and operational costs, its revenue growth across segments and strategic initiatives position the company for continued success in the evolving market landscape.